Cover Image
市場調查報告書

神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) :開發中產品分析

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365748
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) :開發中產品分析 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 72 Pages
簡介

本報告提供以神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) 為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bionomics Limited
  • Catalyst Biosciences, Inc.
  • CoMentis, Inc.
  • FORUM Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NeuroDerm Ltd.
  • Neurodyn Inc.
  • Pfizer Inc.
  • Saniona AB
  • SK Biopharmaceuticals Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0917TDB

Summary:

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 4 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Cognitive Impairment, Parkinson's Disease, Smoking Addiction, Chronic Pain, Complex Regional Pain Syndrome, Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Neurodegenerative Diseases, Neuropathic Pain, Obesity, Pain, Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
    • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
    • Bionomics Ltd
    • Bristol-Myers Squibb Company
    • CoMentis Inc
    • Johnson & Johnson
    • Merck & Co Inc
    • NeuroDerm Ltd
    • Saniona AB
    • SK Biopharmaceuticals Co Ltd
    • Vanda Pharmaceuticals Inc
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
    • (nicotine + opipramol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQW-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-8168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-910731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-375 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gln-1062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBP-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKLA-4R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
      • May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention
      • Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
      • Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase
      • Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder
      • Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
      • Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
      • Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial
      • Mar 29, 2016: Neurodyn Cognition to Present Memogain Clinical Developments at Neurotech Investing and Partnering Conference
      • Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
      • Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression
      • Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety
      • Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210
      • Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting
      • Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Bionomics Ltd, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by CoMentis Inc, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by NeuroDerm Ltd, H2 2017
  • Pipeline by Saniona AB, H2 2017
  • Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
  • Pipeline by Vanda Pharmaceuticals Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top